600165 ST宁科生物
2025/122024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-14.124-630.484-141.042-31.724-19.240
总资产报酬率 ROA (%)-3.881-21.032-14.906-6.409-5.002
投入资产回报率 ROIC (%)-7.569-55.433-24.808-9.274-6.613

边际利润分析
销售毛利率 (%)-19.955-19.539-34.6210.084-32.934
营业利润率 (%)-24.842-162.216-172.692-39.561-74.861
息税前利润/营业总收入 (%)-29.372-125.849-130.799-25.362-62.638
净利润/营业总收入 (%)-36.648-167.102-180.357-40.912-76.166

收益指标分析
经营活动净收益/利润总额(%)147.92850.91660.90792.31693.760
价值变动净收益/利润总额(%)-215.84814.378-6.631-14.389-21.262
营业外收支净额/利润总额(%)30.1053.2664.3021.5670.459

偿债能力分析
流动比率 (X)2.7720.1130.1060.1530.289
速动比率 (X)2.3610.0590.0550.0870.155
资产负债率 (%)46.34688.91789.66575.07967.822
带息债务/全部投入资本 (%)-0.16867.90059.72848.21240.677
股东权益/带息债务 (%)-34,638.58533.56010.18954.84777.844
股东权益/负债合计 (%)104.6723.7263.73922.74834.358
利息保障倍数 (X)-4.761-3.008-2.634-1.710-4.984

营运能力分析
应收账款周转天数 (天)67.17364.58656.53715.54347.113
存货周转天数 (天)74.04486.28795.59575.511122.267